BT-549 Cells

BT-549 cells are a human breast cancer cell line derived from the mammary gland tissue of a 72-year-old Caucasian woman with ductal carcinoma. They are commonly utilized in cancer research to study the biology and treatment of breast cancer, particularly the triple-negative subtype, which lacks estrogen receptor, progesterone receptor, and HER2 expression. BT-549 cells are characterized by their epithelial morphology and are known for their highly invasive properties, making them a valuable model for studying metastasis and tumor invasion. They exhibit several distinctive features including the presence of lipid droplets in the cytoplasm and a robust expression of the mucin-1 protein. These cells also express various oncogenes and tumor suppressor genes that are relevant to breast cancer pathology, such as TP53 and RB1. The BT-549 cell line is estrogen receptor-negative, progesterone receptor-negative, and does not amplify HER2, thus categorizing it under the triple-negative breast cancer (TNBC) subtype. Due to this classification, BT-549 cells are particularly useful for studying the unique mechanisms of progression and treatment response in TNBC, which is known for its aggressive nature and lack of targeted therapies. Furthermore, BT-549 cells are often used in drug resistance studies and for testing new chemotherapeutic agents and targeted therapies, offering insights into potential therapeutic strategies for managing and treating aggressive forms of breast cancer.